Entera Bio Ltd. Additional Paid In Capital

Additional Paid In Capital of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Additional Paid In Capital growth rates and interactive chart.


Highlights and Quick Summary

  • Additional Paid In Capital for the quarter ending June 29, 2020 was $65.7 Million (a 2.39% increase compared to previous quarter)
  • Year-over-year quarterly Additional Paid In Capital increased by 27.51%
  • Annual Additional Paid In Capital for 2019 was $63.4 Million (a 28.92% increase from previous year)
  • Annual Additional Paid In Capital for 2018 was $49.2 Million (a 1623.55% increase from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Additional Paid In Capital of Entera Bio Ltd.

Most recent Additional Paid In Capitalof ENTX including historical data for past 10 years.

Interactive Chart of Additional Paid In Capital of Entera Bio Ltd.

Entera Bio Ltd. Additional Paid In Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $65.74 $64.21
2019 $63.39 $51.56 $49.34 $49.17 $63.39
2018 $49.17 $0.0 $0.0 $0.0 $49.17
2017 $2.85 $2.85

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.